{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T07:54:03Z","timestamp":1789890843447,"version":"4.0.1"},"reference-count":71,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81071876"],"award-info":[{"award-number":["81071876"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81201549"],"award-info":[{"award-number":["81201549"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81272644"],"award-info":[{"award-number":["81272644"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81472247"],"award-info":[{"award-number":["81472247"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002412","name":"Xi\u2019an Jiaotong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2015.00300","type":"journal-article","created":{"date-parts":[[2016,1,18]],"date-time":"2016-01-18T09:24:28Z","timestamp":1453109068000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":48,"title":["New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials"],"prefix":"10.3389","volume":"6","author":[{"given":"Kai","family":"Qu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zichao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hulin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2016,1,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1084\/jem.20041393","article-title":"Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis.","volume":"201","author":"Abdollahi","year":"2005","journal-title":"J. Exp. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1055\/s-0029-1192052","article-title":"Liver transplantation: the current situation.","volume":"29","author":"Adam","year":"2009","journal-title":"Semin. Liver Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/art.24186","article-title":"Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.","volume":"60","author":"Akhmetshina","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.2174\/138945010792006807","article-title":"Tyrosine kinase receptor transactivation associated to G protein-coupled receptors.","volume":"11","author":"Almendro","year":"2010","journal-title":"Curr. Drug Targets"},{"key":"B5","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1124\/jpet.105.084145","article-title":"Role of tyrosine kinase inhibitors in cancer therapy.","volume":"315","author":"Arora","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1038\/sj.bjc.6602584","article-title":"Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on\/7 days off in patients with advanced, refractory solid tumours.","volume":"92","author":"Awada","year":"2005","journal-title":"Br. J. Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.bbadis.2012.06.008","article-title":"Tyrosine kinase signaling in fibrotic disorders: translation of basic research to human disease.","volume":"1832","author":"Beyer","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"B8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1042\/CS20120052","article-title":"Sorafenib treatment improves hepatopulmonary syndrome in rats with biliary cirrhosis.","volume":"124","author":"Chang","year":"2013","journal-title":"Clin. Sci. (Lond.)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"5472","DOI":"10.1158\/1078-0432.CCR-04-2658","article-title":"Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors.","volume":"11","author":"Clark","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"e16978","key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016978","article-title":"Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.","volume":"6","author":"Coriat","year":"2011","journal-title":"PLoS ONE"},{"key":"B11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/ajh.20486","article-title":"Imatinib mesylate as a cause of acute liver failure.","volume":"81","author":"Cross","year":"2006","journal-title":"Am. J. Hematol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1172\/JCI19603","article-title":"Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.","volume":"114","author":"Daniels","year":"2004","journal-title":"J. Clin. Invest."},{"key":"B13","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1517\/14656566.4.6.963","article-title":"Imatinib mesylate in the treatment of chronic myeloid leukaemia.","volume":"4","author":"Druker","year":"2003","journal-title":"Exp. Opin. Pharmacother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10787-011-0092-6","article-title":"Prevention and treatment of Schistosoma mansoni-induced liver fibrosis in mice.","volume":"19","author":"El-Agamy","year":"2011","journal-title":"Inflammopharmacology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/nrd2380","article-title":"Molecular basis for sunitinib efficacy and future clinical development.","volume":"6","author":"Faivre","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","article-title":"Mechanisms of hepatic fibrogenesis.","volume":"134","author":"Friedman","year":"2008","journal-title":"Gastroenterology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/hep.26898","article-title":"Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma.","volume":"59","author":"Fuchs","year":"2014","journal-title":"Hepatology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1124\/jpet.106.114496","article-title":"Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells.","volume":"321","author":"Gonzalo","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/nrd3297","article-title":"Targeting non-malignant disorders with tyrosine kinase inhibitors.","volume":"9","author":"Grimminger","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"B20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11481-013-9484-2","article-title":"Targeting the PDGF signaling pathway in the treatment of non-malignant diseases.","volume":"9","author":"Heldin","year":"2014","journal-title":"J. Neuroimmune Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1476-5381.2009.00158.x","article-title":"Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis.","volume":"157","author":"Hennenberg","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-pathol-011110-130246","article-title":"Pathogenesis of liver fibrosis.","volume":"6","author":"Hernandez-Gea","year":"2011","journal-title":"Annu. Rev. Pathol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10620-012-2325-y","article-title":"Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo.","volume":"58","author":"Hong","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1111\/eci.12006","article-title":"The influence of sorafenib on hepatic encephalopathy and the mechanistic survey in cirrhotic rats.","volume":"42","author":"Hsu","year":"2012","journal-title":"Eur. J. Clin. Invest."},{"key":"B25","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1111\/bcp.12231","article-title":"Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy.","volume":"77","author":"Iacovelli","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s11605-011-1764-7","article-title":"Imatinib mesylate improves liver regeneration and attenuates liver fibrogenesis in CCL4-treated mice.","volume":"16","author":"Kuo","year":"2012","journal-title":"J. Gastrointest. Surg."},{"key":"B27","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00280-005-0068-6","article-title":"Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics.","volume":"57","author":"Lathia","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3350\/kjhep.2007.13.3.309","article-title":"[The role of activated hepatic stellate cells in liver fibrosis, portal hypertension and cancer angiogenesis].","volume":"13","author":"Lee","year":"2007","journal-title":"Korean J. Hepatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/jgh.12480","article-title":"Beneficial effects of dual vascular endothelial growth factor receptor\/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats.","volume":"29","author":"Lin","year":"2014","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"159","key":"B30","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-015-0380-5","article-title":"Combination of sorafenib and gadolinium chloride (GdCl3) attenuates dimethylnitrosamine(DMN)-induced liver fibrosis in rats.","volume":"15","author":"Liu","year":"2015","journal-title":"BMC Gastroenterol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/labinvest.2008.127","article-title":"PTK787\/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling.","volume":"89","author":"Liu","year":"2009a","journal-title":"Lab. Invest."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/labinvest.2009.77","article-title":"Therapeutic targeting of the PDGF and TGF-beta-signaling pathways in hepatic stellate cells by PTK787\/ZK22258.","volume":"89","author":"Liu","year":"2009b","journal-title":"Lab. Invest."},{"key":"B33","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jhep.2010.11.035","article-title":"Inhibition of PDGF, TGF-beta, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib.","volume":"55","author":"Liu","year":"2011","journal-title":"J. Hepatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/ajg.2008.41","article-title":"Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.","volume":"104","author":"Llanos","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ejphar.2013.02.026","article-title":"Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis.","volume":"705","author":"Majumder","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/hep.20193","article-title":"Angiogenesis in chronic inflammatory liver disease.","volume":"39","author":"Medina","year":"2004","journal-title":"Hepatology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/hep.22758","article-title":"Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats.","volume":"49","author":"Mejias","year":"2009","journal-title":"Hepatology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/annonc\/mdi310","article-title":"Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on\/7 days off in patients with advanced, refractory solid tumors.","volume":"16","author":"Moore","year":"2005","journal-title":"Ann. Oncol."},{"issue":"e92273","key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092273","article-title":"Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling.","volume":"9","author":"Nakamura","year":"2014","journal-title":"PLoS ONE"},{"key":"B40","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jhep.2005.06.015","article-title":"Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term.","volume":"44","author":"Neef","year":"2006","journal-title":"J. Hepatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1158\/1078-0432.CCR-11-2484","article-title":"Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.","volume":"18","author":"Peer","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1365-2036.2011.04896.x","article-title":"The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma\u2013a pilot study.","volume":"35","author":"Pinter","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"9443","DOI":"10.1158\/0008-5472.CAN-07-1473","article-title":"Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation.","volume":"67","author":"Plastaras","year":"2007","journal-title":"Cancer Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.gcb.2010.05.007","article-title":"Antiangiogenic therapies in portal hypertension: a breakthrough in hepatology.","volume":"34","author":"Rosmorduc","year":"2010","journal-title":"Gastroenterol. Clin. Biol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"76","DOI":"10.2174\/156800908783497113","article-title":"Small molecule tyrosine kinase inhibitors: potential role in pediatric malignant solid tumors.","volume":"8","author":"Rossler","year":"2008","journal-title":"Curr. Cancer Drug. Targets"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1111\/j.1572-0241.2008.01982_19.x","article-title":"Sorafenib-induced liver failure.","volume":"103","author":"Schramm","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40264-013-0048-4","article-title":"Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1016\/j.bbamcr.2013.02.033","article-title":"Nilotinib induces apoptosis and autophagic cell death of activated hepatic stellate cells via inhibition of histone deacetylases.","volume":"1833","author":"Shaker","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"B49","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1472-8206.2010.00824.x","article-title":"Nilotinib counteracts thioacetamide-induced hepatic oxidative stress and attenuates liver fibrosis progression.","volume":"25","author":"Shaker","year":"2011a","journal-title":"Fundam. Clin. Pharmacol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.ejphar.2011.08.041","article-title":"Comparison of early treatment with low doses of nilotinib, imatinib and a clinically relevant dose of silymarin in thioacetamide-induced liver fibrosis.","volume":"670","author":"Shaker","year":"2011b","journal-title":"Eur. J. Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.taap.2011.02.004","article-title":"Comparison of imatinib, nilotinib and silymarin in the treatment of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis.","volume":"252","author":"Shaker","year":"2011c","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/1440-1681.12286","article-title":"Tracking anti-fibrotic pathways of nilotinib and imatinib in experimentally induced liver fibrosis: an insight.","volume":"41","author":"Shiha","year":"2014","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1590\/1414-431X20143962","article-title":"Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model.","volume":"48","author":"Stefano","year":"2015","journal-title":"Braz. J. Med. Biol. Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1634\/theoncologist.12-4-426","article-title":"Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.","volume":"12","author":"Strumberg","year":"2007","journal-title":"Oncologist"},{"key":"B55","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/hep.24427","article-title":"Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis.","volume":"54","author":"Thabut","year":"2011","journal-title":"Hepatology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.jhep.2010.07.004","article-title":"Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension?","volume":"53","author":"Thabut","year":"2010","journal-title":"J. Hepatol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.jvir.2012.04.007","article-title":"Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration.","volume":"23","author":"Theysohn","year":"2012","journal-title":"J. Vasc. Interv. Radiol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3892\/etm.2010.131","article-title":"Sorafenib suppresses the cell cycle and induces the apoptosis of hepatocellular carcinoma cell lines in serum-free media.","volume":"1","author":"Tomizawa","year":"2010","journal-title":"Exp. Ther. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s12032-009-9284-y","article-title":"Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors.","volume":"27","author":"Tonyali","year":"2010","journal-title":"Med. Oncol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1002\/hep.21921","article-title":"Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats.","volume":"46","author":"Tugues","year":"2007","journal-title":"Hepatology"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1096\/fj.04-2370com","article-title":"Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo.","volume":"19","author":"Wang","year":"2005","journal-title":"FASEB J."},{"key":"B62","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jhep.2010.02.027","article-title":"New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis.","volume":"53","author":"Wang","year":"2010","journal-title":"J. Hepatol."},{"issue":"e95462","key":"B63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095462","article-title":"The effect of antifibrotic drugs in rat precision-cut fibrotic liver slices.","volume":"9","author":"Westra","year":"2014a","journal-title":"PLoS ONE"},{"key":"B64","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.taap.2013.11.017","article-title":"Precision-cut liver slices as a model for the early onset of liver fibrosis to test antifibrotic drugs.","volume":"274","author":"Westra","year":"2014b","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1158\/0008-5472.CAN-10-0163","article-title":"Receptor tyrosine kinase coactivation networks in cancer.","volume":"70","author":"Xu","year":"2010","journal-title":"Cancer Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1042\/CS20140823","article-title":"CD147 promotes liver fibrosis progression via VEGF-A\/VEGFR2 signalling-mediated cross-talk between hepatocytes and sinusoidal endothelial cells.","volume":"129","author":"Yan","year":"2015","journal-title":"Clin. Sci (Lond.)"},{"key":"B67","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/liv.12299","article-title":"Anti-VEGFR agents ameliorate hepatic venous dysregulation\/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat.","volume":"34","author":"Yang","year":"2014","journal-title":"Liver Int."},{"key":"B68","first-page":"899","article-title":"Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-beta with a combination of imatinib mesylate and ACE inhibitor in rats.","volume":"17","author":"Yoshiji","year":"2006","journal-title":"Int. J. Mol. Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1136\/gut.52.9.1347","article-title":"Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis.","volume":"52","author":"Yoshiji","year":"2003","journal-title":"Gut"},{"key":"B70","doi-asserted-by":"publisher","first-page":"G907","DOI":"10.1152\/ajpgi.00420.2004","article-title":"Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats.","volume":"288","author":"Yoshiji","year":"2005","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00108-011-2818-3","article-title":"Tyrosin kinase inhibitors in oncology.","volume":"52","author":"Zander","year":"2011","journal-title":"Internist"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"deposited":{"date-parts":[[2016,2,4]],"date-time":"2016-02-04T10:35:56Z","timestamp":1454582156000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/Article\/10.3389\/fphar.2015.00300\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,18]]},"references-count":71,"URL":"https:\/\/doi.org\/10.3389\/fphar.2015.00300","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,18]]}}}